Two receptor targets
CJC-1295 is studied at the GHRH receptor; Ipamorelin at the growth-hormone secretagogue receptor (GHS-R1a). Different receptors, different literatures.
These are results measured on this lot. Full material specification is in Know your compound.
Growth Hormone Secretagogue
A blend pairing a GHRH analog with a ghrelin-receptor pentapeptide.
$50.00 per vial with BOGO
Research use only — not for human or veterinary use, diagnostic or therapeutic.
Know your compound
This blend combines CJC-1295 without DAC (a 29-residue analog of growth-hormone-releasing hormone) with Ipamorelin (a five-residue ghrelin-receptor agonist). They are two different molecules acting at two different receptors, which is the reason the pairing is studied at all.
The research rationale is that GHRH analogs and growth-hormone secretagogues engage separate upstream pathways in the somatotroph, so the published literature examines them as complementary tools rather than interchangeable ones. The work in this area is predominantly endocrine pharmacology in animal and in-vitro models.
Supplied as a lyophilized powder for laboratory research use only, with the ratio stated on the lot Certificate of Analysis.
Blend ratio is stated on the lot Certificate of Analysis.
What the molecule is.
How we know the material matches the label.
What arrives, and how it is kept.
What the literature examines
Summaries of what published research has investigated. Preclinical unless stated otherwise — not claims about this product.
CJC-1295 is studied at the GHRH receptor; Ipamorelin at the growth-hormone secretagogue receptor (GHS-R1a). Different receptors, different literatures.
Published endocrine work treats releasing-hormone analogs and secretagogues as acting on distinct upstream steps, which is the basis for studying them together.
Certificate of Analysis
Not a brand-wide spec sheet — a lot-specific certificate from an independent laboratory, published before the lot ships and searchable by lot number forever.
Independent U.S. laboratory
Certificate of Analysis · RFX-2606-043
| Test | Specification | Result |
|---|---|---|
| Purity (HPLC) | ≥ 99.0% | 99.4% |
| Identity (LC-MS) | Conforms | Conforms |
| Appearance | White powder | Conforms |
| Net content | Label claim | Conforms |
Questions
No. CJC-1295 / IPA Blend is not an FDA-approved drug and is not approved for human or veterinary use. It is supplied exclusively as a research material for laboratory use, and it is not intended to diagnose, treat, cure, or prevent any disease.
Yes. Every lot is assayed by an independent U.S. laboratory for purity and identity, and the certificate for the lot you receive is published in our COA library — you can read it before you order.
Purity is quantified by reverse-phase HPLC against a reference standard, and identity is confirmed by mass spectrometry. Both results appear on the lot certificate.
Lyophilized material is typically stored cold and protected from light. Handling and storage are the responsibility of the receiving laboratory; refer to the lot documentation for specifics.
Every second vial is free, sitewide and automatically. Add two vials and you pay for one; add six and you pay for three. Compounds can be mixed, there is no code, and there is no limit.
Orders are processed promptly and shipped with tracking. Free US shipping applies over $100; Priority shipping is $8.95 otherwise.
The guarantee
Have any lot independently re-tested. If the results don't match the purity printed on its published certificate, we refund the order in full — no returns, no argument.